Immutep Advances Cancer Trial With FDA Approval
Immutep Gains Positive Feedback From FDA on Phase 3 NSCLC Candidate Program
Immutep Announces Successful Meeting With FDA On Phase III Design In Non-Small Cell Lung Cancer; TACTI-004 Registrational Trial Will Enrol ~750 Patients Regardless Of PD-L1 Expression In Order To Address The Entire 1l NSCLC Market Eligible For...
Immutep Secures US FDA Guidance for Phase Three Lung Cancer Trial
Immutep Readies Phase III Lung Cancer Trial
Jefferies Remains a Buy on Immutep Ltd (PRRUF)
Immutep Receives Regulatory Clearance For Phase I Study Of First-In-Class LAG-3 Agonist Antibody Designed To Treat Autoimmune Diseases
Analysts' Top Healthcare Picks: UnitedHealth (UNH), Immutep (IMMP)
Immutep Set to Begin Landmark Autoimmune Therapy Trial
Capital One Financial Maintains Immutep(IMMP.US) With Buy Rating, Cuts Target Price to $8
Maxim Group Maintains Immutep(IMMP.US) With Buy Rating, Maintains Target Price $12
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Immutep (IMMP)
Buy Rating Affirmed: Immutep's Efti Shows Promising Results in HNSCC Therapy
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
Top Midday Gainers
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Sector Update: Health Care Stocks Mixed Premarket Friday
Sector Update: Health Care
Market-Moving News for July 12th